Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy
- 17 September 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 44 (11), 559-564
- https://doi.org/10.1097/coc.0000000000000864
Abstract
Purpose: The aim of this study was to report local failure (LF) outcomes and associated predictors in patients with oligometastatic colorectal cancer (CRC) treated with stereotactic ablative radiotherapy (SABR). Materials and Methods: We retrospectively reviewed patients with CRC metastases to the brain, liver, spine, or lung treated with SABR between 2001 and 2016. Time to LF was summarized using cumulative incidence of LF curves with death as a competing risk. Results: The analysis included a total of 130 patients and 256 lesions. Of the metastases treated, 129 (50%) were brain, 50 (20%) liver, 49 (19%) spine, and 28 (11%) lung. Median gross tumor volume was 24 mL for liver metastases, 2 mL for brain metastases, 4 mL for spine metastases, and 1 mL for lung metastases. The overall 1, 2, and 3-year cumulative incidence of LF rates were 21.6% (16.5, 27.1), 28.2% (22.3, 34.4), and 31.5% (25.2, 38.0), respectively. LF was highest among the liver metastases (1 y: 26.0%, 2 y: 38.5%), followed by spine (1 y: 25.1%, 2 y: 31.1%), brain (1 y: 20%, 2 y: 25.2%), and lung (1 y: 13.7%, 2 y: insufficient data). Metastases from right-sided primary CRC were significantly more likely to have LF (P=0.0146, HR=2.23). Biologically effective dose>70 Gy, defined using a standard linear quadratic model using α/β ratio of 10 on the individual lesion level, and pre-SABR chemotherapy were also significant predictors of LF (P= 0.0009 and 0.018, respectively). Conclusions: CRC metastases treated with SABR had significantly higher rates of LF if they originated from right-sided primary CRC, compared with left-sided. Liver metastases had the highest rates of LF compared with other metastatic sites. Thus, CRC liver metastases and metastases from right-sided CRC may benefit from more aggressive radiotherapy.Keywords
This publication has 31 references indexed in Scilit:
- Japanese Multi-institutional Study of Stereotactic Body Radiation Therapy for Totally 380 Patients With Lung MetastasesInternational Journal of Radiation Oncology*Biology*Physics, 2014
- Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approachBMC Cancer, 2014
- Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung TumorsInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancerRadiotherapy and Oncology, 2011
- Dose Escalation for Metastatic Spinal Cord Compression in Patients With Relatively Radioresistant TumorsInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Stereotactic body radiotherapy for colorectal liver metastasesCancer, 2011
- Epidemiology and Management of Liver Metastases From Colorectal CancerAnnals of Surgery, 2006
- Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor marginJournal of Neurosurgery, 2006
- Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancerInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Laparoscopic resection of hepatic colorectal metastasesHPB, 2004